Lucid Diagnostics (NASDAQ:LUCD) Posts Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) released its quarterly earnings results on Monday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06), Zacks reports.

Lucid Diagnostics Trading Down 0.3 %

NASDAQ LUCD traded down $0.01 during trading on Monday, reaching $1.52. The company’s stock had a trading volume of 451,854 shares, compared to its average volume of 353,014. The stock has a market capitalization of $89.90 million, a PE ratio of -1.32 and a beta of 1.34. The business has a 50-day moving average price of $1.20 and a 200-day moving average price of $0.98. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.63.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets dropped their price target on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Lucid Diagnostics currently has an average rating of “Buy” and a consensus price target of $3.63.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.